Vitaliy Katsenelson Gilead Sciences’ Miracle Drug Combination Investors stand to benefit from Gilead’s top-selling hepatitis C and HIV drugs even as the biotech company is trading at a discount. Vitaliy Katsenelson February 23, 2016